Riskpilot← Back to searchSign inGet full accessAlzeCure Pharma AB
ABActiveOrg 5590948302Hälsovägen 7Research and experimental development on natural sciences and engineering · NACE 7210Est. 201611 employees
Revenue 2024
SEK 0
EBITDA margin
—
+6% vs 2023
Equity ratio
76.0%
Financial strength
Net profit 2024
SEK -35,2M
+5% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -36,1M | +6% |
| Net profit | SEK -35,2M | +5% |
| Total assets | SEK 34,4M | +8% |
| Equity | SEK 26,2M | +10% |
| Employees | 11 | — |
Legal name
AlzeCure Pharma AB
Org number
5590948302
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
29 december 2016
Share capital
SEK 2 207 000
Employees
11 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Firman tecknas i förening av Jönsson, John Erik Martin Pollare, Thomas Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska direkt eller indirekt, bedriva forskning, utveckling, tillverkning, förvärv och försäljning av läkemedel och diagnostik samt idka därmed förenlig verksamhet.
Address
Hälsovägen 7
Phone
+46703738824
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | — | — |
| EBITDA | −10 767 | −35 893 | −50 908 | −71 579 | −77 926 | −56 442 | −38 262 | −36 144 |
| Depreciation & amort. | −0 | −0 | −0 | — | — | — | — | — |
| EBIT | −10 767 | −35 893 | −50 908 | −71 579 | −77 926 | −56 442 | −38 262 | −36 144 |
| Net financials | −55 | −92 | 50 | 213 | 145 | 203 | 1 095 | 910 |
| Profit before tax | −10 822 | −35 985 | −50 858 | −71 366 | −77 781 | −56 239 | −37 167 | −35 234 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −10 822 | −35 985 | −50 858 | −71 366 | −77 781 | −56 239 | −37 167 | −35 234 |
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 55 971 | 237 782 | 186 755 | 117 827 | 45 647 | 70 836 | 32 001 | 34 435 |
| Equity | 51 825 | 233 169 | 182 007 | 110 755 | 32 974 | 60 482 | 23 774 | 26 185 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 4 146 | 4 613 | 4 748 | 7 072 | 12 673 | 10 354 | 8 227 | 8 250 |
| Total debt | 4 146 | 4 613 | 4 748 | 7 072 | 12 673 | 10 354 | 8 227 | 8 250 |
EBITDA margin
-3614400000.0%
This company
15.8%
Market median
-22875949467% vs market
20172024
Equity ratio
76.0%
This company
38.2%
Market median
+99% vs market
20172024
Return on equity
-134.6%
This company
18.4%
Market median
-832% vs market
20172024
Net profit margin
-3523400000.0%
This company
8.1%
Market median
-43498765532% vs market
20172024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20172024
Debt / equity
0.32×
This company
0.62×
Market median
+48% vs market
20172024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2016-12-01 – 2017-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
EC Chief Auditor | Chief Auditor | 2020 | — | — |
JE Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of AlzeCure Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Eva Camilla Nilsson | Chief Auditor | 0 companies |
| John Erik Martin Jönsson | Chief Executive Officer | 0 companies |
| Thomas Pollare | Chairman | 0 companies |
| Annigje van Es Johansson | Board of Directors | 0 companies |
| Ellen Kinson Donnelly | Board of Directors | 0 companies |
| Pirkko Vilja Päivikki Tamsen | Board of Directors | 0 companies |
| Adriana Jannetje Hoogstraate | Board of Directors | 0 companies |
| Eva Maria Lilienberg | Board of Directors | 0 companies |
| Jan Magnus Lundberg | Board of Directors | 0 companies |
| Carl Ragnar Kurt Linder | Board of Directors | 0 companies |